PRS-060

DRUG2 trials

Sponsors

Pieris Australia Pty Ltd

Conditions

AsthmaHealthy Subjects

Phase 1

Study of a Single Dose of PRS-060 Administered by Oral Inhalation or IV Infusion in Healthy Subjects

CompletedNCT03384290

Pieris Australia Pty LtdHealthy Subjects

Start: 2017-12-08End: 2018-10-11Updated: 2020-11-16

Study of Multiple Doses of PRS-060 Administered by Oral Inhalation in Subjects With Mild Asthma

CompletedNCT03574805

Pieris Australia Pty LtdAsthma

Start: 2018-06-26End: 2020-09-15Updated: 2020-12-24

Related Papers

Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma

2019-09-285 citations

Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra

2019-09-285 citations

AZD1402/PRS-060, an inhaled Anticalin® IL-4Ra antagonist, potently inhibits IL-4 induced functional effects in human whole blood, which can be employed translationally in clinical studies

2018-09-152 citations